A Constrained Hierarchical Bayesian Model Considering Latent Biomarker Subgroups for Time-To-Event Endpoints in Randomized Phase II Trials
{{output}}
In randomized Phase III oncology trials, the long-term time-to-event endpoint is the most relevant outcome for participants and regulators. However, in Phase II trials, the short-term binary outcome of tumor response is often used as a surrogate endpoint to ev... ...
